DLA Piper’s broad offering regularly handles cross-border joint ventures, private equity investment mandates, and clinical trial agreements for its lucrative, global client base of pharma and biotech companies. Practice head Roberto Valenti is well-equipped to assist clients with the full range of soft IP disputes and commercial issues surrounding medical devices. Marco de Morpurgo divides his time between Rome and Brussels, with his primary area of expertise being EU and Italian regulation of biotech, medical devices, and pharma products. Regulatory expert Nicola Landolfi is known for his vast knowledge of both EU and Italian law governing the licensing of products and clinical trials. Raffaella Quintana left the team in 2025.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Billing & efficiency
Client satisfaction: Sector knowledge
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
- 'Very well-prepared and skilled.'
- 'Roberto Valenti is very prepared and talented in understanding issues and favouring solutions.'
Key clients
- Pfizer Italia S.r.l.
- Pfizer S.r.l.
Work highlights
Assisted the Pfizer Group in relation to all aspects of Italian law relating to the integration of Seagen's Italian business into Pfizer's Italian business, completed by means of the merger by incorporation of Seagen Italy S.r.l. with and into Pfizer S.r.l.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Practice head
Roberto Valenti
Other key lawyers
Marco de Morpurgo; Gualtiero Dragotti; Nicola Landolfi